Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MIEXIA

Financiado

Mitochondria-Inflammation crosstalk and EXercise-induced pathways in cachexIA

Cancer cachexia (CC) affects 50-80% of patients with cancer and is characterized by accelerated loss of muscle mass, which is directly linked to reduced quality of life, treatment toxicity, and lower survival. With no pharmacologi... ver más

30/06/2025

UCPH

231K€

Presupuesto del proyecto: 231K€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-28

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UCPH

230.77K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-65589-P REGULACION DE LA CONVERSION DEL TEJIDO ADIPOSO BLANCO EN MAR... 202K€ Cerrado

SAF2008-02284 MIOSTATINA Y CAQUEXIA CANCEROSA: PERDIDA DE MASA MUSCULAR Y... 109K€ Cerrado

SAF2011-26091 TERAPIA COMBINADA COMO ESTRATEGIA PARA EL TRATAMIENTO DE LA... 109K€ Cerrado

MyoTumour A novel role for skeletal muscle in tumour growth and prolif... 173K€ Cerrado

RTI2018-099413-B-I00 DESENMASCARANDO NUEVOS GENES EN EL CONTROL DEL METABOLISMO D... 315K€ Cerrado

SAF2017-87988-R PAPEL Y POTENCIAL TERAPEUTICO DE LA RESPUESTA A PROTEINAS DE... 242K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2023-03-28
Fecha Fin: 2025-06-30

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 231K€

Descripción del proyecto Cancer cachexia (CC) affects 50-80% of patients with cancer and is characterized by accelerated loss of muscle mass, which is directly linked to reduced quality of life, treatment toxicity, and lower survival. With no pharmacological treatment options, key to improving life expectancy is to understand the molecular determinants of CC, however, these are poorly defined. Mitochondrial dysfunction and inflammation can cause muscle atrophy and are considered as emerging hallmarks of CC. Exercise is the most potent approach to improve mitochondrial and muscle function, and to reduce inflammation, yet, implementing it in CC is challenging because of fatigue and pain of patients with cancer. Elucidating the molecular underpinnings of exercise’s beneficial effects represents a major scientific challenge and an untapped opportunity for medical exploitation. In this regard, unpublished data from my host lab show that muscle protein levels of the mitochondrial (mt) RNA stabilizer LRPPRC (Leucine-rich PPR motif-containing protein) are induced upon exercise and reduced in cachectic muscles. Thus, mtRNA metabolism could be a new target for CC. mtRNA metabolism is key to maintain levels of mtDNA-encoded proteins to promote mitochondrial function. Yet LRPPRC´s role in muscle mitochondrial function and CC is unexplored. I hypothesize that reduced LRPPRC is key in CC-associated muscle mitochondrial dysfunction and inflammation. Stimulation of LRPPRC could promote exercise-like benefits, establishing a new pharmacological target for CC. I aim to determine the molecular link between mitochondrial dysfunction, inflammation, and muscle atrophy in preclinical CC models and patients with CC. I will unravel the molecular pathways involved in LRRPRC’s exercise-induced effects and I will appraise LRPPRC’s therapeutic potential in CC. Results have the potential to provide crucial insights on the molecular events underlying CC and likely identify new pharmacological strategies to tackle it.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores